

DIRECTORS REPORT

Dear Members,

Your directors have pleasure in presenting the 11th Annual report on the affairs of the Company together with the Audited standalone and consolidated Statement of Accounts for the financial year ended on 31st March, 2021.

1. FINANCIAL PERFORMANCE OF THE COMPANY:

(Figure In ₹)

PARTICULARS	STANDALONE		CONSOLIDATED	
	2020-21	2019-20	2020-21	2019-20
Revenue from Operations	1,65,73,84,517.36	85,05,99,283.47	1,71,41,12,952.40	84,96,42,674.47
Other Income	44,37,382.15	1,26,14,510.13	44,37,382.15	13,59,36,660.13
Total Revenues	1,66,18,21,899.51	86,32,13,793.60	1,71,85,50,334.55	86,32,36,334.60
Profit before Financial Expenses, Preliminary expenses, Depreciation and Taxation	37,93,11,006.63	27,64,94,013.70	43,60,39,441.67	27,65,16,554.70
Less: Financial expenses	2,43,27,258.56	89,62,625.76	2,43,27,258.55	89,62,625.76
Profit before Depreciation & Taxation	35,49,83,748.07	26,75,31,387.94	41,17,12,183.12	26,75,53,928.94
Less: Depreciation & amortization expenses	93,48,708.90	89,55,115.50	93,48,708.90	89,55,115.50
Operating Profit before Other expenses & Taxation	34,56,35,039.17	25,85,76,272.44	40,23,63,474.22	25,85,98,813.44
Less: Other expenses	15,67,26,237.32	11,47,27,923.33	21,70,79,165.70	11,63,85,041.33
Profit before Taxation	18,89,08,801.85	14,38,48,349.11	18,52,84,308.52	14,22,13,772.11
Less: Provision for Taxation				
Current Tax	4,89,41,260.00	4,27,80,652.27	4,80,29,047.00	4,23,04,663.45
Deferred Tax	(4,10,665.73)	(6,98,306.77)	(4,10,665.73)	19,09,422.86
Profit for the period	14,03,78,207.58	10,17,66,003.61	13,76,65,927.25	9,79,99,685.80

2. RESULT OF OPERATIONS AND STATE OF AFFAIRS

During the fiscal year 2020-21 the total Standalone revenue of the Company stood at 1,66,18,21,899.51 and consolidated revenue stood at ₹1,71,85,50,334.55.

The standalone profit of the Company in fiscal year ending on March, 31, 2021 has been reported as ₹14,03,78,207.58 and the consolidated profit is ₹13,76,65,927.25.

3. TRANSFER TO RESERVES:

The Company has transferred ₹45,74,32,941.88/- to Reserve and Surplus account by the end of fiscal year 2021.

Q-LINE BIOTECH PRIVATE LIMITED (Formerly known as "POCT Services Pvt. Ltd.")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adj. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023

Delhi. Office: C-108, NARAINA INDUSTRIAL AREA PHASE -1, New Delhi, New Delhi, Delhi, 110028. Tel.: 011-45577407

E-mail: info@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PTC042528

4. DIVIDEND:

The Board has not declared any Dividend during the financial year 2020-21.

5. FINANCIAL STATEMENTS:

The audited Financial Statements of the Company, which form a part of this Annual Report, have been prepared in accordance with the provisions of the Companies Act, 2013, prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

6. MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR:

The Company has changed its Name to Q-Line Biotech Private Limited w.e.f. 23rd July, 2021 as per approval of shareholders and Ministry of Corporate Affairs.

Further, in terms of Section 134(3)(l) of the Companies Act, 2013, except as disclosed elsewhere in this Report, no material changes and commitments which could affect the Company's financial position have occurred between the end of the financial year of the Company and date of this Report.

7. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

During the year under review there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

8. SUBSIDIARIES/JOINT VENTURE/ASSOCIATE COMPANY:

As on March 31, 2021, the Company had the following subsidiaries/Associate/Joint Venture.

Sl. No.	Name of the Subsidiary/ Associate/Joint Venture	Relationship
1.	POCT Science House Pvt. Ltd.	Joint Venture

The company holds 50% equity stake in POCT Science House Pvt. Ltd., a joint venture entered into with Science House Medicals Pvt. Ltd. for providing lab services on Wet Lease Basis Reagent Rental in Government Health facilities in Madhya Pradesh. The Company has reported total turnover of Rs. 11,34,56,870.08/-

9. STATUTORY AUDITORS & AUDIT REPORT:

M/s Mayank Mehrotra & Associates, Chartered Accountants, Lucknow (Firm Registration Number 022941C) were appointed as the Statutory Auditors of the Company to hold office for a term of 05 years from the conclusion of the 07th Annual General Meeting held on 30th September, 2017 until the conclusion of the 12th Annual General Meeting of the Company to be held in the year 2022.

There are no qualifications or observations or remarks made by the Auditors in their Report. Hence no comments are required to be made in the Directors Report

10. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP) & CHANGES IN THE BOARD OF DIRECTORS

No changes have taken place during the year 2020-21, in the Board of Company.

In view of the applicable provisions of the Companies Act, 2013, the Company is not mandatorily required to appoint any whole time KMPs.

11. NUMBER OF MEETING OF THE BOARD & CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:

During the year 2020-21, the Board of Directors met twelve times to transact the business of the Company. Two meetings of the Committee were held during Financial Year 2020-21.

12. DEPOSITS:

The Company has not invited/ accepted any deposits from the public during the year ended March 31, 2021. There were no unclaimed or unpaid deposits as on March 31, 2021.

13. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, is annexed herewith as “Annexure-I”.

14. CORPORATE SOCIAL RESPONSIBILITY:

Pursuant to the requirement of Section 135 of the Companies Act, 2013, a Corporate Social Responsibility (‘CSR’) committee has been formed by the Company. The CSR Committee of the Board has formed with three Directors that comprises Mr. Saurabh Garg, Mrs. Amita Garg and Mr. Abhay Agrawal, Directors of the Company.

Role of Corporate Social Responsibility Committee:

The role of the Corporate Social Responsibility Committee is as follows:

- (1) formulate and recommend to the Board, the Corporate Social Responsibility Policy and the activities to be undertaken by the Company, review the implementation and progress of the same from time to time.
- (2) recommend the amount of expenditure to be incurred on the activities
- (3) monitor the Corporate Social Responsibility Policy from time to time
- (4) discharge such duties and functions as indicated in the section 135 of the Companies Act, 2013 and Rules made thereunder from time to time and such other functions as may be delegated to the Committee by the Board from time to time.
- (5) take all necessary actions as may be necessary or desirable and also to settle any question or difficulty or doubts that may arise with regards to Corporate Social Responsibility activities/Policy of the Company.

The Corporate Social Responsibility Committee has formulated and recommended to the Board, a Corporate Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company, which has been approved by the Board. The key focus areas of the CSR Policy are under;

- (i) **Education:** To work on several educational initiatives to provide quality education, training, skill enhancement for *improving* the quality of *living* and *livelihood*. Initiatives are aimed at:
 - a) Promoting primary and secondary education
 - b) Imparting Skill development and vocational training

- c) Using sports as a tool for development of students in both urban and rural settings
 - d) Promoting higher education including setting up and supporting skill development centres, Industrial Training Centre.
- (ii) **Health:** To address issues around affordability and accessibility of quality healthcare and bring about improvement in awareness and health seeking behaviour in various parts of India, enabling a better living, through initiatives such as:
- a) Upgrading Primary, secondary and tertiary care facilities
 - b) Conducting need based health camps and providing consultation, medicines etc.
 - c) Working on maternal and child health
 - d) Improving healthcare delivery through innovative outreach programmes
 - g) Working in the areas of Communicable and non-communicable diseases
 - h) Using technology for training, competency evaluation and clinical decision support for medical professionals with a view to improve quality of healthcare.
- (iii) **Environment:** To enable enhanced livelihood and quality of life, promote environment sustainability through various initiatives for:
- a) Ecological sustainability
 - b) Promoting biodiversity
 - c) Conservation of natural resources
 - d) Maintaining quality of soil, air and water
 - e) Promoting renewable energy
 - f) Developing gardens and river fronts
- (iv) **Other Initiatives:** To undertake other need based initiatives in compliance with Schedule VII of the Companies Act, 2013.

The company is committed to conduct its business in a socially responsible, ethical and environment friendly manner and to continuously work towards improving quality of life of the communities in its operational areas as we believe that the sustainable development of our business is dependent on sustainable, long lasting and mutually beneficial relationships with our stakeholders, especially the communities we work with. As a responsible corporate citizen, we have a role to play in the integrated and inclusive development of the country, in partnership with government, corporates and civil society/community institutions. We also believe that our employees have the potential to contribute not just to our business, but also towards the goal of building strong communities.

The company is committed to comply with section 135 of the Act and the approach is focused on long term programmes aligned with community needs. CSR activities, as per the Companies Act, 2013, may be undertaken by the Company directly or through registered not for profit company, trust or a registered society.

The Annual report on CSR activities is annexed herewith marked as 'Annexure-II'

15. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the requirement under section 134(3)(C) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- a. In the preparation of the annual accounts for the financial year ended 31st March, 2021, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b. the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2021 and of the Surplus and loss of the company for that period;
- c. the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d. the directors have prepared the annual accounts on a going concern basis; and
- e. the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

16. PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE:

The Company has in place a policy on Prevention of Sexual Harassment at Workplace. All employees, consultants, trainees, third parties and/or visitors at all business units or functions of the Company, its subsidiaries and/or its affiliated or group companies are covered by the said policy. The Company is in compliance with the provisions relating to the constitution of an Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

17. DECLARATION BY INDEPENDENT DIRECTORS:

The Company was not required to appoint Independent Directors under Section 149(4) and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 hence no declaration has been obtained.

18. COMPANY'S POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION INCLUDING CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES, INDEPENDENCE OF A DIRECTOR AND OTHER MATTERS PROVIDED UNDER SUB-SECTION (3) OF SECTION 178:

The Company, being a Private Limited Company under the Companies Act, 1956 (now the Companies Act, 2013) is not required to constitute a Nomination and Remuneration Committee under Section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178(5) of the Companies Act, 2013.

19. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:

During the year under review, the Company has not advanced any loans/ given guarantees/ made investments under the provisions of Section 186 of the Companies Act, 2013.

20. PARTICULARS OF EMPLOYEES:

None of the employee has received remuneration exceeding the limit as stated in rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

21. EXTRACT OF THE ANNUAL RETURN IN FORM MGT-9:

Pursuant to section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014, the details forming part of the extract of the Annual Return in form MGT-9 is annexed herewith as "Annexure-III".

22. BUSINESS RISK MANAGEMENT:

Pursuant to section 134 (3) (n) of the Companies Act, 2013 the company has not constituted a business risk management committee.

At present the company has not identified any element of risk which may threaten the existence of the company.

23. RELATED PARTY TRANSACTIONS:

Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 are mentioned in the form AOC-2:


24. ACKNOWLEDGMENT:

Your Directors take this opportunity to place on record their appreciation and sincere gratitude to the Members of the Company, Bankers and other Financial Institutions, Government of India, State Government, Local Bodies, Customers & Suppliers, of the Company for their valuable support and look forward to their continued co-operation in the years to come.

Your Directors acknowledge the support and co-operation received from the employees at all levels and consultants for their continuous co-operation and assistance in management and day to day operation of the Company.

**FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF
Q-LINE BIOTECH PRIVATE LIMITED**


(Saurabh Garg)
Director
DIN: 02891621


(Amita Garg)
Director
DIN: 02891610

Date: 09.11.2021
Place: Lucknow

ANNEXURE – I

Information under Section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 and forming part of the Report of the Directors

(A) Conservation of energy-

- (i) the steps taken or impact on conservation of energy: NIL
- (ii) the steps taken by the company for utilizing alternate sources of energy: NIL
- (iii) the capital investment on energy conservation equipments: NIL

(B) Technology absorption-

- (i) the efforts made towards technology absorption: NIL
- (ii) the benefits derived like product improvement, cost reduction, product development or import substitution: NIL
- (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year): NIL
- (iv) the expenditure incurred on Research and Development: NIL


(C) Foreign exchange earnings and Outgo-


During the financial year 2020-21 the total foreign exchange outgo for Rs. NIL has taken place in the ordinary course of business.

**FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF
Q-LINE BIOTECH PRIVATE LIMITED**

Date: 09.11.2021

Place: Lucknow


(Saurabh Garg)
Director
DIN: 02891621


(Amita Garg)
Director
DIN: 02891610

ANNEXURE – II
CORPORATE SOCIAL RESPONSIBILITY (CSR)

[Pursuant to clause (o) of sub-section (3) of section 134 of the Act and Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014]

1. A brief outline of the Company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs: **Refer Point 14, i.e., Corporate Social Responsibility, of the Board report.**
2. The Composition of the CSR Committee: **Refer Point 14, i.e., Corporate Social Responsibility, of the Board report.**
3. Average net profit of the company for last three financial years: **Rs. 139,507,904.67/-**
4. Prescribed CSR Expenditure (two per cent of the amount as in item 3 above): **Rs. 27,90,158.09/-**
5. Details of CSR spent during the financial year.
 - (a) Total amount to be spent for the financial year: **Rs. 44,28,884.85/-**
 - (b) Amount unspent, if any: **Rs. 5,11,117.85/-**
 - (c) Manner in which the amount spent during the financial year is detailed below.

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
S. No	CSR project or activity identified	Sector in Which the Project is covered	Projects or programs (1) Local area or other (2) Specify the State and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise (in Lacs)	Amount spent on the projects or programs Sub – heads: (1) Direct expenditure on projects or programs (2) Overheads (in Lacs)	Cumulative expenditure upto to the reporting period (in Lacs)	Amount spent: Direct or through implementing agency*
1	Upgrading Healthcare facilities	Promoting Health Care & Medical Facilities	Uttar Pradesh- Lucknow	50.00	39.18	39.18	Direct
TOTAL				50.00	39.18	39.18	

6. In case the Company has failed to spend two per cent of the average net profit of the last three financial years or any part thereof, the Company shall provide the reasons for not pending the amount in its Board report: The Company always endeavor to meet the budgeted CSR expenditure by contributing in various eligible CSR activities to improve the quality of life and health of community where it is working and to achieve this objective the company always strive to develop and implement such projects. Being a healthcare company engaged in diagnostic sector the company had visualized the upcoming pandemic of COVID- 19 and its severity on the community at large and accordingly has strategically formalized its CSR plans to strengthen the healthcare facilities in its local area. Due to the adverse impact of covid on working and our precautionary approach to deal with the same the formulation of project had taken a longer time than the expected, thereby the company had spent only **Rs. 39.18 Lakh** in the F.Y. 2020-21 and the remaining unspent amount of **Rs. 05.11 Lakh** was incurred by the company in its CSR projects for strengthening the health care facility of the local area within next six months from the closure of F.Y. 2020-21.

7. Responsibility Statement of the CSR Committee: The implementation and monitoring of CSR Policy, is in compliance with CSR objectives and Policy of the Company.

Q-LINE BIOTECH PRIVATE LIMITED

Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED

Amita Garg
Director

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis:

There were no contracts or arrangements or transactions entered in to during the year ended March 31, 2021, which were not at arm's length basis.

2. Details of contracts or arrangements or transactions at Arm's length basis:

Name(s) of the related party	Nature of Relationship	Duration of contract	Salient terms	Dates of Approval by the Board	Amount Rs.	Amount paid as advances, if any
Nature of Contract: SALES OF GOODS						
Heidelco Medico Pvt. Ltd.	Associated Enterprise	NA	NA	NA	10,19,14,050.00	Nil
POCT Services	Associated Enterprise	NA	NA	NA	38,43,06,237.00	Nil
POCT Science House Pvt. Ltd.	Associated Enterprise	NA	NA	NA	63,16,931.00	Nil
Nature of Contract: RENT PAID						
Heidelco Medico Pvt. Ltd.	Associated Enterprise	NA	NA	NA	5,90,004.00	Nil
POCT Services	Associated Enterprise	NA	NA	NA	6,00,000.00	Nil
Nature of Contract: SALARY & INCENTIVE						
Saurabh Garg	Director	NA	NA	NA	4,20,00,000.00	Nil
Amita Garg	Director	NA	NA	NA	3,00,00,000.00	Nil
Kuldeep Chowdhry	Director	NA	NA	NA	30,00,000.00	Nil
Ajay Kumar Mahanty	Director	NA	NA	NA	61,25,000.00	Nil
Manisha Yadav	Director	NA	NA	NA	18,00,000.00	Nil
Amit Agarwal	Relative	NA	NA	NA	18,75,000.00	Nil
Ayush Garg	Relative	NA	NA	NA	24,00,000.00	Nil
Nature of Contract: PURCHASE OF GOODS						

Q-LINE BIOTECH PRIVATE LIMITED

Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED

Amita Garg
Director

Heidelco Medico Pvt. Ltd.	Associated Enterprise	NA	NA	NA	29,91,983.00	Nil
POCT Services	Associated Enterprise	NA	NA	NA	8,41,25,777.00	Nil
Nature of Contract: RENT INCOME						
POCT Services	Associated Enterprise	NA	NA	NA	50,000.00	Nil
POCT Quality & Skill Development Foundation	Associated Enterprise	NA	NA	NA	1,20,000.00	Nil

Q-LINE BIOTECH PRIVATE LIMITED
Suman Chandra
 Director

Q-LINE BIOTECH PRIVATE LIMITED
Anita Chandra
 Director